Loading…
Employees: 981
Size Newland Pharmaceutical (301277.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $523M, the 3751st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥8.90 on 6 Nov 2026.
Performance Over six months the shares fell 21.9%, against -16.1% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 9.4% over the last twelve months (peer median +9.8%); the operating margin is 11.5% (peer median 6.8%).
Valuation It trades at 3.9× enterprise value to sales against a peer median of 3.7× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.9 points above its cost of capital (6.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥734M | CN¥670M | CN¥724M | CN¥648M | CN¥624M |
| Revenue growth | — | -7% | +12% | +4% | — |
| Gross profit | CN¥243M | CN¥210M | CN¥269M | CN¥242M | CN¥210M |
| EBITDA | n/a | CN¥177M | CN¥221M | CN¥194M | CN¥170M |
| Net income | CN¥93.0M | CN¥121M | CN¥174M | CN¥159M | CN¥132M |
| Free cash flow | CN¥41.6M | CN¥25.8M | CN¥30.2M | CN¥181M | CN¥8.84M |
| Capital expenditure | CN¥36.8M | CN¥101M | CN¥111M | CN¥96.5M | CN¥74.3M |
| Total debt | CN¥3.73M | CN¥5.69M | CN¥3.83M | CN¥2.72M | CN¥17.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301277.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.1% | -8.0% | 7th lowest of 21 |
| 6-month return | -21.9% | -16.1% | 9th lowest of 21 |
| Distance from 52-week high | -35.7% | -35.7% | 11th highest of 21 |
| Revenue growth (TTM) | +9.4% | +9.8% | 10th lowest of 20 |
| Operating margin | 11.5% | 6.8% | 7th highest of 18 |
| EV / Sales | 3.9× | 3.7× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 10.2% | 1.4% | 4th most demanding of 9 |
| Growth delivered (Del g) | +9.1% | +8.6% | 5th highest of 9 |
| Hurdle (Req g minus delivered) | +1.1 pp | -13.1 pp | 4th most demanding of 9 |
| ROIC minus cost of capital | +4.9 pp | -3.1 pp | 5th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |